Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4979252, 6 pages
https://doi.org/10.1155/2017/4979252
Research Article

A Robust PCR Protocol for HIV Drug Resistance Testing on Low-Level Viremia Samples

1Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
2The Bioinformatics Core, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
3National HIV & Retrovirology Laboratories, JC Wilt Infectious Diseases Research Center, Public Health Agency of Canada, Winnipeg, MB, Canada
4Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada
5Cadham Provincial Laboratory, Winnipeg, MB, Canada
6Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada

Correspondence should be addressed to Hezhao Ji; ac.cg.cpsa-cahp@ij.oahzeh

Received 21 January 2017; Revised 14 March 2017; Accepted 21 March 2017; Published 3 April 2017

Academic Editor: György Schneider

Copyright © 2017 Shivani Gupta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Esparza, “The global HIV vaccine enterprise,” International Microbiology, vol. 8, pp. 93–101, 2005. View at Google Scholar
  2. R. Sitnik and J. R. R. Pinho, “Quantitation of HIV-1 RNA viral load using nucleic acid sequence based amplification methodology and comparison with other surrogate markers for disease progression,” Memórias do Instituto Oswaldo Cruz, vol. 93, no. 3, pp. 411–415, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. T. L. Kieffer, M. M. Finucane, R. E. Nettles et al., “Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads,” Journal of Infectious Diseases, vol. 189, no. 8, pp. 1452–1465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Yang, A. McNulty, K. Diallo et al., “Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance,” Journal of Clinical Microbiology, vol. 48, no. 9, pp. 3158–3164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Zhou, N. Wagar, J. R. DeVos et al., “Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings,” PLoS ONE, vol. 6, no. 11, Article ID e28184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Cohen, “Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen,” HIV Clinical Trials, vol. 10, no. 2, pp. 116–124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Santoro, L. Fabeni, D. Armenia et al., “Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels,” Clinical Infectious Diseases, vol. 58, no. 8, pp. 1156–1164, 2014. View at Publisher · View at Google Scholar
  8. A. Gonzalez-Serna, J. E. Min, C. Woods et al., “Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals,” Clinical Infectious Diseases, vol. 58, no. 8, pp. 1165–1173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Laprise, A. De Pokomandy, J.-G. Baril, S. Dufresne, and H. Trottier, “Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation,” Clinical Infectious Diseases, vol. 57, no. 10, pp. 1489–1496, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. L. Villahermosa, M. Thomson, E. Vázquez De Parga et al., “Improved conditions for extraction and amplification of human immunodeficiency virus type 1 RNA from plasma samples with low viral load,” Journal of Human Virology, vol. 3, no. 1, pp. 27–34, 2000. View at Google Scholar · View at Scopus
  11. H. Mens, M. Kearney, and A. Wiegand, “Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays,” Journal of Visualized Experiments, no. 55, Article ID e2960, 2011. View at Publisher · View at Google Scholar
  12. H. Hatano, E. L. Delwart, P. J. Norris et al., “Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals,” AIDS, vol. 24, no. 16, pp. 2535–2539, 2010. View at Publisher · View at Google Scholar
  13. L. Vancoillie, V. Mortier, E. Demecheleer et al., “Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART,” Antiviral Therapy, vol. 20, no. 8, pp. 789–794, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. Qiagen, QIAamp Viral RNA Mini Handbook, vol. 2014, Qiagen, Hilden, Germany, 4th edition.
  15. B. Foley, T. Leitner, C. Apetrei et al., Eds., HIV Sequence Compendium, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2014.
  16. M. Hermankova, S. C. Ray, C. Ruff et al., “HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy,” Journal of the American Medical Association, vol. 286, no. 2, pp. 196–207, 2001. View at Publisher · View at Google Scholar · View at Scopus